![Martha Rook](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martha Rook
Geschäftsführer bei
DELCATH SYSTEMS, INC.
Vermögen: 82 607 $ am 31.05.2026
Profil
Martha S.
Rook is Chief Operating Officer at Delcath Systems, Inc. since 2024.
Former roles include Secretary & Director at Alliance for Regenerative Medicine, VP, Head-Gene Editing & Novel Modalities at EMD Millipore Corp.
from 2016 to 2018, Chief Technical Operations Officer at Sigilon Therapeutics, Inc. from 2021 to 2022, and Chief Technical Operations Officer at Insitro, Inc. from 2022 to 2024.
Education includes undergraduate studies at Texas A&M University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DELCATH SYSTEMS, INC. 0,02 % | 16.03.2026 | 7 663 ( 0,02 % ) | 82 607 $ | 31.05.2026 |
Aktive Positionen von Martha Rook
| Unternehmen | Position | Beginn |
|---|---|---|
| DELCATH SYSTEMS, INC. | Geschäftsführer | 18.03.2024 |
Ehemalige bekannte Positionen von Martha Rook
| Unternehmen | Position | Ende |
|---|---|---|
Insitro, Inc.
 Insitro, Inc. BiotechnologyHealth Technology Operates as a biology based AI therapeutics company | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2024 |
| SIGILON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 07.03.2022 |
EMD Millipore Corp.
 EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of biotechnology & pharmaceutical drug therapies | Corporate Officer/Principal | 01.01.2018 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Direktor/Vorstandsmitglied | - |
Ausbildung von Martha Rook
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
41
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
EMD Millipore Corp.
EMD Millipore Corp. Miscellaneous Commercial ServicesCommercial Services Engages in research, development and production of biotechnology & pharmaceutical drug therapies | Commercial Services |
Delcath Systems, Inc.
 Delcath Systems, Inc. Medical SpecialtiesHealth Technology Develops and manufactures drugs for treatment of cancer | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Texas A&M University
 Texas A&M University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
Sigilon Therapeutics, Inc.
 Sigilon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapeutic treatments for chronic diseases | Health Technology |
Insitro, Inc.
Insitro, Inc. BiotechnologyHealth Technology Operates as a biology based AI therapeutics company | Health Technology |
